Latest News on Aurobindo Pharma
Aurobindo Pharma experiences a bearish technical reversal due to its poor performance and stagnant growth.
Aurobindo Pharma, a midcap pharmaceutical company, has recently undergone a change in evaluation, with technical indicators now reflecting a bearish outlook. The company’s technical trend has shifted from mildly bearish to bearish, as indicated by various metrics such as Moving Averages, Bollinger Bands, and MACD. The Moving Averages signal a bearish trend on a daily basis, while the Bollinger Bands also reflect bearish conditions on both weekly and monthly timelines.
The company’s performance over the past year has been underwhelming, with a return of -28.31%, significantly underperforming the broader market, which recorded a slight decline of -2.13%. Aurobindo Pharma’s operating profit growth has been modest, averaging 4.40% annually over the last five years, and recent quarterly results have shown stagnation. Despite these challenges, the company maintains a low debt-to-equity ratio, which is a positive sign.
In terms of valuation, Aurobindo Pharma appears to be reasonably valued, with a return on equity of 10.7 and a price-to-book value of 1.9. These metrics suggest that the company is fairly valued relative to its peers. However, the bearish technical indicators and underwhelming performance over the past year suggest that investors should exercise caution when considering Aurobindo Pharma as a potential investment opportunity.
The company’s struggles over the past year can be attributed to various factors, including increased competition in the pharmaceutical sector and challenges in maintaining profit growth. Despite these challenges, Aurobindo Pharma’s low debt-to-equity ratio and reasonable valuation metrics provide a positive outlook for the company’s long-term prospects. Nevertheless, investors should closely monitor the company’s technical indicators and performance metrics to determine the best course of action.
Overall, Aurobindo Pharma’s bearish technical indicators and underwhelming performance over the past year suggest that the company is facing significant challenges. However, its low debt-to-equity ratio and reasonable valuation metrics provide a positive outlook for the company’s long-term prospects. Investors should exercise caution and closely monitor the company’s performance and technical indicators before making any investment decisions.
Aurobindo Group’s housing division plans to raise $225 million through an Indian bond issuance to finance a major acquisition.
Auro Realty, the real estate division of the Aurobindo Group, is planning to raise ₹20 billion ($225.41 million) through a bond sale to finance a significant acquisition. The Aurobindo Group also owns Aurobindo Pharma, a prominent drug manufacturer. According to two merchant bankers, the bond issue is in advanced stages and may be completed as early as this month. The bonds will have a tenure of two and four years, with interest rates ranging from 11% to 15%.
The funds raised from the bond sale will be used to acquire several assets, including the Hotel Taj Banjara Hyderabad. This move is part of a growing trend of companies using the corporate bond market to fund large acquisitions. The Aurobindo Group did not respond to a request for comment, while the merchant bankers chose to remain anonymous due to lack of authorization to speak to the media.
The bond issue is expected to attract investment from private credit funds. As a reliable and trusted news source, it is essential to note that the bond market has become an increasingly popular route for companies to raise funds for acquisitions, expansions, and other business purposes. This trend is driven by the relatively low cost of borrowing and the flexibility offered by bond issues.
The Aurobindo Group’s decision to raise funds through a bond sale demonstrates its confidence in the bond market and its ability to attract investors. The group’s real estate arm, Auro Realty, is likely to use the funds raised to expand its portfolio and strengthen its position in the market. With the bond issue expected to be completed soon, it will be interesting to see how the company utilizes the funds and how it impacts the group’s overall business strategy.
As a trusted news source, it is crucial to provide accurate and timely information about market trends and developments. The rising trend of companies tapping the corporate bond market for funding large acquisitions is a significant development that warrants attention. With its strong reputation and financial capabilities, the Aurobindo Group is well-positioned to take advantage of this trend and achieve its business objectives.
China’s reduction in import duties helps alleviate the impact of US tariffs on India’s pharmaceutical industry.
The Indian pharmaceutical industry is facing a complex global trade landscape, with contrasting developments in China and the US. China has reduced import duties on Indian pharma products by 30%, effectively enabling near-zero-cost access, providing a significant growth opportunity in a key Asian market. On the other hand, the US has announced a 100% tariff on imported branded and patented drugs, effective October 2025, which will put pressure on Indian companies reliant on US sales.
Companies such as Aurobindo Pharma, Lupin, and Sun Pharma have high US revenue exposure, making them vulnerable to the tariff. Aurobindo Pharma has a 46.7% exposure, Lupin has 35.8%, and Sun Pharma has 32.7%. In contrast, companies like Cipla, with a 14.1% exposure, are relatively insulated due to their focus on generics.
The US tariff primarily targets branded and patented drugs, which may exempt generics. However, the uncertainty surrounding the tariff’s scope and impact on generics can impede strategic planning and operational continuity. China’s reduced import duties, on the other hand, significantly improve the cost competitiveness of Indian exports, offering a valuable alternative market to mitigate US exposure.
To navigate this complex landscape, Indian pharmaceutical companies should consider strategic adjustments, such as portfolio segmentation, market diversification, and capex and manufacturing strategy. They should distinguish between US tariff-sensitive products and less vulnerable categories, expand their footprint in China and other Asian markets, and consider US production facilities to gain tariff exemptions.
Companies can leverage China’s favorable policies to diversify revenue streams, enhance margins, and mitigate geopolitical trade risks. Continuous monitoring of policy developments, revenue allocations, and strategic investments will be critical for Indian pharma to sustain global competitiveness in this dynamic landscape. By doing so, Indian pharmaceutical exporters can capitalize on growth opportunities in China and other markets, while minimizing the impact of the US tariff on their business.
Five pharmaceutical companies, including Sun Pharma and Zydus, have issued recalls for their products in the US market.
Sun Pharma, Zydus, and three other pharmaceutical companies have issued recalls for their products in the US market. The recalls were initiated due to various reasons, including contamination, labeling issues, and deviations from manufacturing standards.
Sun Pharma, one of India’s largest pharmaceutical companies, has recalled several batches of its products, including tablets and capsules, due to concerns over contamination and labeling errors. The company has stated that the affected products were manufactured at its facilities in India and were shipped to the US market.
Zydus, another major Indian pharmaceutical company, has also recalled several products, including tablets and injectables, due to issues with labeling and packaging. The company has cited manufacturing deviations as the reason for the recall.
The other three companies that have issued recalls are Accord Healthcare, Aurobindo Pharma, and Dr. Reddy’s Laboratories. Accord Healthcare has recalled several batches of its products, including tablets and capsules, due to concerns over contamination and labeling errors. Aurobindo Pharma has recalled several products, including tablets and injectables, due to issues with labeling and packaging. Dr. Reddy’s Laboratories has recalled several batches of its products, including tablets and capsules, due to concerns over contamination and manufacturing deviations.
The US Food and Drug Administration (FDA) has announced the recalls on its website, stating that the affected products may pose a risk to public health. The FDA has advised consumers to stop using the recalled products and return them to the manufacturer or their healthcare provider.
The recalls are a significant concern for the pharmaceutical industry, as they can impact the reputation of the companies involved and potentially harm consumers. The companies have stated that they are taking corrective actions to address the issues that led to the recalls and are working to ensure that their products meet the required standards of quality and safety.
The recalls also highlight the importance of regulatory oversight in ensuring the safety and efficacy of pharmaceutical products. The FDA plays a critical role in monitoring the pharmaceutical industry and taking enforcement actions when necessary to protect public health. The agency’s actions in this regard have helped to maintain the integrity of the US pharmaceutical market and ensure that consumers have access to safe and effective medications.
Aurobindo Pharma Experiences Brief Manufacturing Halt
Aurobindo Pharma, a prominent pharmaceutical company, has reported a fire incident at its wholly-owned subsidiary, APL Healthcare Ltd, located in Naidupeta, Andhra Pradesh. The fire occurred in the granulation area-10 of Unit-IV, a Special Economic Zone (SEZ) unit, due to a short circuit. The blaze spread to a nearby panel, causing partial damage to granulation area-8. Fortunately, the in-house fire hydrant team, along with external fire tenders, quickly controlled the fire, and no casualties or injuries were reported.
The incident has temporarily disrupted production, with two out of 19 production lines impacted. These lines are expected to remain non-operational for approximately two weeks. As a result, the unit’s monthly production has been reduced by about three percent. However, Aurobindo Pharma has assured that it is already working on restoring and refurbishing the affected areas and expects to resume full operations within a few weeks.
The company has emphasized its commitment to ensuring employee safety, safeguarding assets, and minimizing operational disruption. Aurobindo Pharma has implemented all necessary safety measures to protect employees and secure assets, demonstrating its proactive approach to risk management and incident response. The fire incident is not expected to have a material impact on the company’s finances or operations.
Aurobindo Pharma’s swift response to the incident and its ongoing commitment to safety and operations are testaments to its dedication to maintaining operational continuity and protecting its employees and assets. The company’s ability to quickly contain the fire and minimize damage reflects its well-established safety protocols and emergency response procedures. With the affected areas being restored and refurbished, Aurobindo Pharma is expected to bounce back to full operational capacity soon, with minimal long-term impact on its production and finances.
Stock Market Updates for Aurobindo Pharma
Recent Updates
A minor blaze broke out in the granulation section of Aurobindo Pharma’s Unit IV, specifically area-10, according to the company.
Aurobindo Pharma is a pharmaceutical company that focuses on the research, development, manufacturing, and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The company’s products can be categorized into two main families: generic drugs and active pharmaceutical ingredients. The generic drugs offered by Aurobindo Pharma are used to treat a wide range of diseases, including neurological, cardiovascular, viral, gastroenterological, ophthalmologic, and chronic diseases.
As of March 2018, Aurobindo Pharma operated a total of 23 production sites across three countries: India, the United States, and Brazil. The majority of these production sites, 19, are located in India, while the remaining four are split between the United States, with three sites, and Brazil, with one site. This global presence enables the company to manufacture and supply its products to various markets around the world.
In terms of its sales, Aurobindo Pharma generates revenue from several geographic regions. The company’s net sales are distributed as follows: 12% from India, 46.5% from the United States, 31.2% from Europe, and 10.3% from other regions. This indicates that the United States is the company’s largest market, accounting for nearly half of its total sales. Europe is also a significant market for Aurobindo Pharma, contributing over 30% to the company’s net sales.
Overall, Aurobindo Pharma is a major player in the pharmaceutical industry, with a diverse portfolio of products and a global presence. The company’s focus on generic drugs and active pharmaceutical ingredients has enabled it to establish a strong position in the market, with a significant presence in several geographic regions. With its extensive network of production sites and diverse sales distribution, Aurobindo Pharma is well-positioned to continue growing and expanding its operations in the future. The company’s commitment to research, development, and manufacturing has enabled it to become a leading provider of affordable and high-quality pharmaceuticals to patients around the world.
Prominent pharmaceutical companies such as Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, and Torrent Pharma are navigating the complexities of the pharma value chain.
The pharmaceutical industry is complex, with various segments such as innovator products, generics, branded generics, and API. Indian companies are making headway globally, and understanding the industry’s intricacies is crucial for those seeking opportunities. Innovator companies undertake significant risks, with only 8 out of 100 molecules crossing the finish line, and patent protection is the incentive for undertaking this risk. Roche, a leading innovator, reported a 30% PAT margin in FY24, with R&D expenses at 20% of sales.
Indian pharma is sustained by generics, but companies like Sun Pharma and Glenmark Pharma are making modest beginnings in innovation. Sun Pharma’s innovative medicine segment has 11 products, including Ilumya, which reported sales of $680 million in FY25. Glenmark Pharma’s Ichnos Glenmark Innovation (IGI) recently entered a licensing agreement with AbbVie for its ISB 2001, receiving $700 million in milestone payments.
The generics business is dependent on the level of competition, with prices declining sharply as the number of competitors increases. Branded generics, however, offer higher value, with companies like Mankind Pharma and Torrent Pharma generating significant revenues from their branded portfolios. Complex generics, such as Lupin’s generic Spiriva, hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
Biosimilars are a growing segment, with companies like Biocon developing portfolios. The biosimilar approval process involves clinical trials, increasing the cost of development to $200-300 million. CRDMO (contract research and development and manufacturing outsourcing) is another emerging segment, with companies like Divi’s Labs and Anthem Biosciences securing a portion of the innovators’ drug development process.
The API business is largely commoditized, with prices dependent on tonnage. However, high-potent APIs and complex manufacturing processes can fetch higher margins. India has focused on API development with its PLI schemes, and companies like Aurobindo Pharma are establishing API facilities.
For investors, a strong branded generic base supplemented by a wide innovator portfolio is essential for trail-blazing growth. Complex generics and CRDMO are emerging sectors, with China+1 and the US Biosecure Act providing tailwinds. The right mix of business segments and prospects is crucial for growth, and understanding the industry’s intricacies is essential for those seeking opportunities in the pharmaceutical sector.
Key takeaways include:
* Innovator companies undertake significant risks, but patent protection provides an incentive.
* Indian pharma is sustained by generics, but companies are making modest beginnings in innovation.
* Branded generics offer higher value, with companies generating significant revenues from their branded portfolios.
* Complex generics hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
* Biosimilars are a growing segment, with companies developing portfolios.
* CRDMO is an emerging segment, with companies securing a portion of the innovators’ drug development process.
* The API business is largely commoditized, but high-potent APIs and complex manufacturing processes can fetch higher margins.
Aurobindo Pharma’s Unit-XII received eight observations.
Aurobindo Pharma, a prominent pharmaceutical company, recently underwent a USFDA (United States Food and Drug Administration) inspection at its Unit-XII facility. The inspection resulted in the issuance of 8 observations, which are essentially a list of deficiencies or areas that require improvement. These observations are a critical aspect of the USFDA’s inspection process, as they highlight specific concerns or non-compliances with regulatory standards.
The USFDA inspection is a rigorous evaluation of a pharmaceutical facility’s adherence to current Good Manufacturing Practices (cGMPs) and other regulatory requirements. The inspection team assesses various aspects of the facility, including its quality control systems, manufacturing processes, and overall compliance with FDA regulations. The issuance of 8 observations at Aurobindo Pharma’s Unit-XII facility indicates that the USFDA inspectors identified several areas that require corrective action.
While the specific details of the observations have not been disclosed, they likely pertain to issues such as inadequate quality control procedures, insufficient documentation, or non-compliance with standard operating procedures (SOPs). The company will be required to respond to these observations and provide a corrective action plan to address the identified deficiencies. This plan will outline the steps the company will take to rectify the issues and prevent future non-compliances.
The receipt of 8 observations may have implications for Aurobindo Pharma’s business operations and reputation. The company may need to invest significant resources to address the identified issues and ensure compliance with regulatory requirements. Additionally, the observations may impact the company’s ability to supply products to the US market, at least until the issues are resolved.
It is worth noting that the USFDA inspection process is designed to ensure the quality and safety of pharmaceutical products. The issuance of observations is a common occurrence during FDA inspections, and many companies receive similar notices. Aurobindo Pharma will need to take prompt and effective action to address the observations and demonstrate its commitment to compliance with regulatory standards. By doing so, the company can maintain its reputation as a reliable and trustworthy pharmaceutical manufacturer.
Aurobindo’s Telangana facility receives Form 483 from USFDA, citing eight major observations.
The US Food and Drug Administration (FDA) recently conducted an inspection of a manufacturing facility in India. The facility, known as Unit-XII, is owned by a Hyderabad-based drug firm and is located in Bachupally, Telangana. The inspection took place from August 25 to September 5.
Unit-XII is a significant facility for the company, as it includes both oral solids and injectable manufacturing units. The FDA inspection was likely a routine evaluation to ensure that the facility is complying with current Good Manufacturing Practices (cGMP) and other regulatory standards.
The Hyderabad-based drug firm made the announcement of the FDA inspection in a regulatory filing. The filing did not provide detailed information about the inspection, such as any findings or observations made by the FDA. However, the fact that the inspection was conducted suggests that the company is engaged in exporting pharmaceutical products to the US market.
The US FDA is responsible for regulating the safety and efficacy of pharmaceutical products in the US. As part of its oversight, the agency conducts regular inspections of manufacturing facilities, both domestic and foreign, to ensure compliance with regulatory standards. These inspections can be lengthy and thorough, involving a review of the facility’s processes, procedures, and quality control systems.
The outcome of the FDA inspection is not yet known, and it may take several weeks or even months for the agency to issue a report or take any regulatory action. If the inspection reveals any significant deficiencies or violations, the company may be required to take corrective action to address these issues.
The FDA inspection of Unit-XII is significant, as it reflects the growing importance of India’s pharmaceutical industry in the global market. India is one of the largest exporters of pharmaceutical products to the US, and many Indian companies have established a significant presence in the US market. The inspection also highlights the need for Indian pharmaceutical companies to maintain high standards of quality and compliance to ensure continued access to the US market.
Overall, the FDA inspection of Unit-XII is a routine evaluation that is part of the agency’s oversight of pharmaceutical manufacturing facilities. While the outcome of the inspection is not yet known, it is likely to have significant implications for the company and the Indian pharmaceutical industry as a whole.
Aurobindo Pharma’s Telangana facility receives 5 observations from the US Food and Drug Administration.
Aurobindo Pharma, a leading pharmaceutical company, has received five observations from the US Food and Drug Administration (USFDA) for its facility in Telangana, India. The observations were made during a recent inspection of the facility, which is a key manufacturing site for the company.
The USFDA inspection was conducted to ensure that the facility is complying with current Good Manufacturing Practices (cGMP) regulations. The observations made by the USFDA are related to various aspects of the facility’s operations, including quality control, documentation, and manufacturing processes.
While the exact nature of the observations has not been disclosed, they are likely to be related to issues such as inadequate documentation, insufficient quality control measures, or non-compliance with standard operating procedures. The company has stated that it is taking immediate action to address the observations and rectify the issues.
Aurobindo Pharma has a strong track record of compliance with regulatory requirements and has made significant investments in its quality systems and manufacturing infrastructure. The company is committed to ensuring that its facilities meet the highest standards of quality and compliance, and it is working closely with the USFDA to resolve the issues.
The receipt of observations from the USFDA is not uncommon, and it is a normal part of the regulatory process. Many pharmaceutical companies receive observations during inspections, and it is an opportunity for them to identify areas for improvement and take corrective action.
Aurobindo Pharma has stated that it is confident that it can resolve the issues and regain compliance with USFDA regulations. The company is working closely with the regulatory agency to address the observations and implement corrective actions. The facility in Telangana is a key manufacturing site for the company, and it is essential that it is operating in compliance with regulatory requirements to ensure the quality and safety of its products.
Overall, the receipt of five observations from the USFDA is a setback for Aurobindo Pharma, but it is an opportunity for the company to identify areas for improvement and take corrective action. The company is committed to ensuring that its facilities meet the highest standards of quality and compliance, and it is working closely with the regulatory agency to resolve the issues. With its strong track record of compliance and commitment to quality, Aurobindo Pharma is confident that it can regain compliance with USFDA regulations and continue to produce high-quality products for its customers.
The U.S. Food and Drug Administration has issued five observations to an active pharmaceutical ingredient plant owned by Aurobindo Pharma’s subsidiary.
The US Food and Drug Administration (FDA) has conducted an inspection of an active pharmaceutical ingredients (API) manufacturing facility owned by Apitoria Pharma, a subsidiary of Aurobindo Pharma. The facility, located in the Sangareddy district near Hyderabad, was inspected from August 21 to 29. Following the inspection, the FDA issued a Form 483, which included five observations regarding the facility’s procedures.
According to Aurobindo Pharma, the observations made by the FDA are procedural in nature, and there were no issues related to data integrity reported. This suggests that the issues identified by the FDA are related to the facility’s operational procedures and do not involve any concerns about the accuracy or reliability of the data generated by the facility.
Aurobindo Pharma has stated that it will respond to the FDA’s observations within the stipulated timelines. The company did not provide any further details about the nature of the observations or the steps it plans to take to address them. The issuance of a Form 483 does not necessarily mean that the facility is in violation of FDA regulations, but rather that the agency has identified areas where the facility can improve its procedures to ensure compliance with regulatory standards.
The inspection and subsequent issuance of a Form 483 are part of the FDA’s ongoing efforts to ensure that pharmaceutical manufacturing facilities, including those located outside the US, comply with its regulations and standards. Aurobindo Pharma is a major pharmaceutical company with a significant presence in the global market, and the outcome of this inspection could have implications for the company’s operations and reputation.
It is worth noting that the FDA’s inspection and observation process is designed to be transparent and collaborative, with the goal of ensuring that pharmaceutical manufacturing facilities operate in a way that prioritizes public health and safety. Aurobindo Pharma’s response to the FDA’s observations will be closely watched by regulators, investors, and other stakeholders, and the company’s ability to address the issues identified by the FDA will be an important factor in determining the outcome of this situation.
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce pharmaceutical expenditure, and growing awareness of cost-effective alternatives. The market is also driven by local manufacturing and government support for generics.
The demand for generic medications in Saudi Arabia is increasing rapidly, driven by the government’s attempts to reduce reliance on imported branded medicines and lower healthcare spending. The Saudi Food and Drug Authority (SFDA) has simplified the process of generic approvals, encouraging local and foreign manufacturers to increase their generic offerings.
Key growth drivers in the Saudi Arabia Generic Drugs Market include government support and cost containment initiatives, increasing incidence of chronic diseases, and growing local production capability. The government has focused on making healthcare more affordable through greater generic drug promotion, and initiatives such as the “Procedure to deal with patents when registering generic products in SFDA” have been introduced to facilitate the growth of the generic drug market.
However, the market also faces challenges, including public perception and brand loyalty, as well as regulatory and quality control complexity. Despite these challenges, the market is expected to continue growing, driven by the increasing demand for cost-effective generic drugs.
The report provides an in-depth analysis of the Saudi Arabia Generic Drugs Market, including market trends, forecast, and key players analysis. The market is segmented by type, route of administration, therapeutic area, distribution channel, and region. Key players in the market include Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group AG, and Sun Pharmaceutical Industries Ltd.
The report also highlights the growing trend of online generic drugs in Saudi Arabia, with digital platforms and e-pharmacies facilitating easier price comparisons and prescription-based generics ordering for consumers. The online generic drug segment is expected to receive robust traction, particularly in urban regions such as Riyadh and Jeddah.
In terms of therapeutic areas, the report highlights the growing demand for generic drugs in areas such as respiratory, oncology, and infectious diseases. The report also provides an analysis of the regulatory framework of generic drugs in Saudi Arabia, including the role of the SFDA and the challenges faced by manufacturers in complying with regulatory requirements.
Overall, the Saudi Arabia Generic Drugs Market is expected to continue growing, driven by government support, increasing demand for cost-effective generic drugs, and growing local production capability. The report provides a comprehensive analysis of the market, including key trends, challenges, and opportunities, and is a valuable resource for companies looking to enter or expand their presence in the Saudi Arabian generic drugs market.
Aurobindo Pharma Foundation provides students with specialised training driven by industry expertise.
On Thursday, a ceremony was held in Pydibhimavaram, Srikakulam district, to award certificates to 28 students who successfully completed a course on “Pharmaceutical Quality Control Analytical Techniques”. The certificates were handed over by K. Kamalakar Reddy, Head and Senior General Manager of the Aurobindo Pharma Foundation, along with management consultant S. Dayanannda. The course is designed to provide practical knowledge and skills to students in the pharmaceutical sector, particularly in the area of quality control and analytical techniques.
According to Mr. Kamalakar Reddy, the establishment of bulk drug industries in India and abroad has created a promising future for students who pursue pharmaceutical and related skill development courses. The Aurobindo Pharma Foundation is supporting M.Sc. graduates to undertake this course, with the aim of providing them with hands-on experience and understanding of the changes taking place in the manufacturing of bulk drugs.
The skill development program is an initiative of the Aurobindo Pharma Foundation, which is committed to promoting education and skill development in the pharmaceutical sector. The program is designed to equip students with the necessary skills and knowledge to pursue a career in the industry. The faculty members and program in-charge, Manohar Reddy, were also present at the ceremony to congratulate the students on their achievement.
The awarding of certificates to the students marks a significant milestone in their academic and professional journey. The course has provided them with a comprehensive understanding of pharmaceutical quality control and analytical techniques, which will enable them to make a valuable contribution to the industry. The Aurobindo Pharma Foundation’s initiative is a step in the right direction, as it addresses the need for skilled professionals in the pharmaceutical sector and provides opportunities for students to acquire practical knowledge and skills.
Overall, the ceremony was a celebration of the students’ achievement and a testament to the Aurobindo Pharma Foundation’s commitment to promoting education and skill development in the pharmaceutical sector. With the growing demand for skilled professionals in the industry, initiatives like this are essential to bridging the gap between academia and industry, and providing students with the necessary skills and knowledge to succeed in their chosen careers.
Aurobindo gains FDA approval for generic version of Pfizer’s Chantix
The US Food and Drug Administration (FDA) has granted approval to Aurobindo Pharma for its varenicline tablets, available in 0.5 mg and 1 mg strengths. This approval marks a significant milestone for Aurobindo, as its varenicline tablets are the generic equivalent of PF Prism C.V.’s Chantix Tablets. The FDA’s green light allows Aurobindo to commercially manufacture and distribute its varenicline tablets, providing patients with a more affordable treatment option for smoking cessation.
Varenicline tablets are specifically designed to aid individuals in quitting smoking, a habit that poses significant health risks. Smoking is a leading cause of preventable deaths worldwide, and quitting can greatly reduce the risk of developing smoking-related illnesses, such as heart disease, lung cancer, and chronic obstructive pulmonary disease (COPD). The varenicline tablets work by reducing cravings for nicotine and blocking the pleasurable effects of smoking, making it easier for individuals to quit.
Aurobindo’s varenicline tablets have undergone rigorous testing and have demonstrated bioequivalence to Chantix Tablets, ensuring that they are therapeutically equivalent and can be used interchangeably. The FDA’s approval of Aurobindo’s varenicline tablets is a testament to the company’s commitment to providing high-quality, affordable generic medications to patients.
The availability of generic varenicline tablets is expected to increase access to smoking cessation treatment, particularly for individuals who may not have been able to afford the brand-name medication. Aurobindo’s varenicline tablets will be marketed at a lower price point than Chantix Tablets, making it a more accessible option for patients. This approval is also expected to drive competition in the market, leading to lower prices and increased innovation in the development of smoking cessation treatments.
Overall, the FDA’s approval of Aurobindo’s varenicline tablets marks a significant step forward in the fight against smoking-related illnesses. By providing a more affordable and accessible treatment option, Aurobindo is helping to make a positive impact on public health. As the company continues to expand its portfolio of generic medications, it is likely to play an increasingly important role in improving access to healthcare for patients around the world.
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India’s position as a global supplier of generic medicines, leading to increased trade volume and job creation. The sector has shown positive momentum in the short term, reflecting a steady rise in investor confidence. Analysts project substantial upside potential for various companies operating in this space.
Several top companies in the sector have been identified as having strong upside potential. Cohance Lifesciences Limited, a technology-driven contract development and manufacturing organization, has a target price of Rs. 1400.00, indicating an upside potential of 33%. Piramal Pharma Limited, a global pharmaceutical company, has a target price of Rs. 271.00, reflecting an upside potential of 32%. Natco Pharma Limited, a vertically integrated pharmaceutical company, has a target price of Rs. 1090.00, indicating an upside potential of 28%.
Other companies with strong upside potential include Aurobindo Pharma Limited, which has a target price of Rs. 1470.00, reflecting an upside potential of 23%, and Blue Jet Healthcare Limited, which has a target price of Rs. 943.00, indicating an upside potential of 19%. Zydus Lifesciences Limited, a global life sciences company, has a target price of Rs. 1040.00, reflecting an upside potential of 18%.
Overall, the outlook for the Indian pharmaceutical sector remains positive, driven by the new trade agreement with the European Union and the growth potential of various companies operating in the space. Analysts recommend a strong buy for Cohance Lifesciences and Piramal Pharma, a buy for Aurobindo Pharma and Blue Jet Healthcare, and a hold for Natco Pharma and Zydus Lifesciences.
The financial performance of these companies has been strong, with many reporting significant year-on-year sales growth. However, some companies have seen a decline in profit after tax (PAT) due to various factors. Despite this, the long-term implications of the trade agreement and the growth potential of the sector are expected to drive growth and innovation in the Indian pharmaceutical industry.
Aurobindo and MSN set to lose US patent protection for Nuplazid in August 2038
A recent US district court ruling has brought relief to Acadia Pharmaceuticals, the manufacturer of Nuplazid, a medication used to treat hallucinations and delusions associated with Parkinson’s disease psychosis. The court’s decision has upheld the validity of a key formulation patent for Nuplazid, which is set to expire in August 2038. This ruling means that generic versions of the medication, including one developed by Aurobindo, will not be able to enter the market until the patent expires.
The court found that Aurobindo’s abbreviated new drug application (ANDA) for a generic version of Nuplazid infringed on Acadia’s patent. Furthermore, the court also ruled that MSN, another company, had already admitted to infringing on the patent. This decision is a significant victory for Acadia, as it protects the company’s exclusive rights to market Nuplazid in the US for several more years.
The ruling is also a blow to generic drug manufacturers, who had been seeking to enter the market with their own versions of Nuplazid. Aurobindo and other companies had been trying to capitalize on the growing demand for treatments for Parkinson’s disease psychosis, which is a significant and underserved market. However, with the court’s decision, these companies will now have to wait until the patent expires in 2038 before they can launch their own generic versions.
The decision is also a testament to the strength of Acadia’s patent portfolio and the company’s ability to defend its intellectual property. Acadia has invested heavily in developing Nuplazid, and the medication has become a key driver of the company’s growth. The court’s ruling ensures that Acadia will be able to continue to reap the benefits of its investment in Nuplazid for several more years.
Overall, the court’s decision is a significant development in the pharmaceutical industry, and it highlights the importance of intellectual property protection in the development of new medications. With the patent for Nuplazid set to expire in 2038, Acadia will have a significant amount of time to continue to market and sell the medication before generic competition enters the market. This will provide the company with a stable source of revenue and allow it to continue to invest in the development of new treatments for Parkinson’s disease and other conditions.
Aurobindo Pharma subsidiary introduces leadership development initiative at Indian Management and Technology Institute Hyderabad
Aurobindo Pharma, a leading generic drug manufacturer, has launched a six-month post-graduation certification in leadership (CLP) program at the Institute of Management Technology, Hyderabad (IMT Hyderabad). The program, introduced through Aurobindo’s wholly-owned subsidiary Apitoria, aims to transform promising professionals into dynamic leaders by equipping them with essential skills in managing themselves, teams, business, and change.
The CLP program consists of 13 days of classroom sessions, spread across six modules, which will be delivered through a blend of traditional and modern teaching methods. The program is designed to be immersive and practice-oriented, providing participants with hands-on experience and real-world applications. The curriculum is tailored to help middle managers develop the skills and confidence needed to take on larger responsibilities and drive business growth.
According to U.N.B. Raju, Senior Vice President of Corporate HR at Aurobindo Pharma, the introduction of the CLP program is a testament to the company’s commitment to nurturing talent and enabling the growth of middle management. “It is an important step in grooming our middle managers to take on larger responsibilities with confidence and agility,” Raju said. The program is expected to play a critical role in connecting strategy with execution, driving business success, and fostering a culture of leadership and innovation within the organization.
The launch of the CLP program is a strategic investment in the development of Aurobindo Pharma’s human capital, recognizing the critical role that middle managers play in driving business growth and success. By partnering with IMT Hyderabad, Aurobindo Pharma aims to provide its employees with access to world-class education and training, empowering them to excel in their roles and contribute to the company’s continued success. With the CLP program, Aurobindo Pharma is poised to develop a pipeline of talented leaders who can drive business growth, innovation, and excellence in the pharmaceutical industry.
The Indian market for active pharmaceutical ingredients has experienced significant revenue generation.
The India Active Pharmaceutical Ingredients (API) market is expected to experience significant growth, with an estimated value of USD 14.81 billion in 2025 and a projected value of USD 25.23 billion by 2032, at a compound annual growth rate (CAGR) of 7.9%. This growth is driven by increasing demand for pharmaceuticals, innovation, and the presence of key players in the market.
The report provides a comprehensive analysis of the India Active Pharmaceutical Ingredients market, including market size, revenue, production, and CAGR. It also highlights the competitive landscape, with key players such as Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Cipla, and Sun Pharmaceutical Industries. The report provides a detailed review of major players, covering their financials, product benchmarking, and competitive strategies.
The market is segmented by manufacturer, synthesis type, drug type, application, product type, and formulation. The report also analyzes the geographical landscape of the market, with a focus on North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
The report identifies key drivers and trends in the market, including technological advancements, regulatory and policy shifts, and emerging industry trends. It also highlights the opportunities and challenges in the market, including supply chain issues and evolving consumer behavior.
The report provides actionable insights and quantitative analysis of market segments, trends, estimations, and dynamics. It also includes Porter’s Five Forces analysis for strategic decision-making and segmentation analysis to identify market opportunities.
The key benefits of the report include:
* Quantitative analysis of market segments, trends, estimations, and dynamics
* Insights into key drivers, restraints, and opportunities
* Porter’s Five Forces analysis for strategic decision-making
* Segmentation analysis to identify market opportunities
* Revenue mapping of major countries by region
* Benchmarking and positioning of market players
* Analysis of regional and global trends, key players, and growth strategies
The report is a valuable resource for industry leaders, investors, and decision-makers, providing a comprehensive and detailed analysis of the India Active Pharmaceutical Ingredients market. It is available for purchase, with a 25% discount for a limited time.
Aurobindo Pharma subsidiary receives US FDA approval for generic version of Bristol Myers Squibb’s cancer treatment
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Dasatinib Tablets in various strengths. The approved product is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company’s (BMS) Sprycel Tablets. Dasatinib Tablets are used to treat certain types of leukemia, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.
The approval is significant, as the estimated market size for the product is $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT numbers. The company plans to launch the product by June. This is the 181st Abbreviated New Drug Application (ANDA) approval received by Eugia Pharma Specialities Group (EPSG) facilities, which manufacture both oncology oral and sterile specialty products.
Dasatinib Tablets are indicated for the treatment of newly diagnosed adults with Ph+ chronic myeloid leukemia in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy. The product is also used to treat adults with Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
The approval demonstrates Aurobindo Pharma’s commitment to expanding its product portfolio and increasing its presence in the global pharmaceutical market. The company’s subsidiary, Eugia Pharma Specialities, has a strong track record of receiving FDA approvals, with 181 ANDA approvals to date. The launch of Dasatinib Tablets is expected to contribute to the company’s revenue growth and help it achieve its business objectives.
Overall, the FDA approval of Dasatinib Tablets is a significant milestone for Aurobindo Pharma and its subsidiary, Eugia Pharma Specialities. The product has the potential to make a significant impact in the treatment of certain types of leukemia, and the company is well-positioned to capitalize on the growing demand for affordable and effective pharmaceuticals.
Aurobindo Pharma secures FDA nod for generic version of Xarelto.
Aurobindo Pharma, a leading Indian pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for the generic equivalent of Xarelto (Rivaroxaban), a popular anticoagulant drug. The generic version, Rivaroxaban Tablets, will be used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone knee or hip replacement surgery.
Xarelto is a blockbuster drug developed by Johnson & Johnson and is marketed by Bayer. According to Aurobindo Pharma, it is one of the most widely used oral anticoagulant drugs, with over 1.5 million prescriptions filled in the US alone in 2020. However, it is notoriously difficult to manufacture and has been the subject of several patent disputes.
Aurobindo Pharma’s generic version of Xarelto is the first to receive FDA approval and will be available in the US market in the coming weeks. The company claims that its generic version is identical in composition, strength, and dosage form to the branded version, and is therefore substitutable.
The approval is significant for Aurobindo Pharma, which has been aggressively pursuing FDA approvals for generic versions of blockbuster drugs. The company has over 200 ANDA (Abbreviated New Drug Application) filings pending with the FDA, including several for complex products such as Xarelto.
The pricing of Aurobindo Pharma’s generic Xarelto will likely be significantly lower than the branded version, which could potentially disrupt the market dynamics. The branded Xarelto is currently priced at around $120 per 20-mg tablet, while Aurobindo Pharma’s generic version will be priced much lower, around $4-5 per tablet.
The generic approval is also seen as a shot in the arm for India’s pharmaceutical industry, which has been under pressure due to rising competition from China and patent-related issues. Aurobindo Pharma’s success will likely encourage other Indian companies to invest in developing generic versions of complex products, which could help to reduce the country’s dependence on branded drugs.
In conclusion, Aurobindo Pharma’s FDA approval for the generic equivalent of Xarelto is a significant development in the pharmaceutical industry, particularly for the Indian company and the country’s pharma sector as a whole. The generic version is expected to be priced lower than the branded version, which could disrupt the market dynamics and provide patients with a more affordable option.
Aurobindo Pharma receives US FDA approval for Rivaroxaban Tablets
Aurobindo Pharma, a generic drugmaker, has received final approval from the US FDA to manufacture and market Rivaroxaban Tablets USP in the strength of 2.5 mg. This approval is based on the company’s demonstration of bioequivalence and therapeutic equivalence to the reference listed drug Xarelto 2.5 mg of Janssen Pharmaceuticals Inc. The company plans to launch the product by June, following the approval.
Rivaroxaban Tablet USP is used to treat various conditions, including nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, and for the prophylaxis of blood clots in patients undergoing knee or hip replacement surgery. The approved product has an estimated US market size of $447 million for the 12 months ending February 2025.
Aurobindo Pharma has also received tentative approval from the US FDA for Rivaroxaban Tablets USP in strengths of 10 mg, 15 mg, and 20 mg. The estimated US market size for all strengths of Rivaroxaban tab USP is $8.5 billion for the 12 months ending February 2025.
Aurobindo Pharma arm CuraTeQ Biologics completes successful Phase 1 pharmacokinetic study of investigational bone drug.
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has successfully completed a Phase 1 pharmacokinetics study for its investigational bone drug. The study aimed to evaluate the drug’s ability to maintain a stable level in the bloodstream over a prolonged period.
The Phase 1 study was a randomized, open-label, single-dose escalation design, involving 24 healthy male subjects. Participants received a single dose of the investigational bone drug, and pharmacokinetic (PK) parameters were measured to assess the drug’s absorption, distribution, metabolism, and elimination (ADME) profile.
The study results showed that the investigational bone drug was well-tolerated, with no serious adverse events reported. The study also demonstrated that the drug follows a predictable PK profile, with a rapid absorption and elimination, and a relatively small variability in exposure across participants.
The successful completion of this study is a significant milestone for CuraTeQ Biologics, as it sets the stage for further clinical development of the investigational bone drug. The company plans to continue evaluating the safety and efficacy of the drug in larger, more detailed studies, with the goal of submitting a new drug application to regulatory authorities in the future.
The investigational bone drug, a humanized monoclonal antibody, is being developed as a potential treatment for osteoporosis and related bone disorders. It is designed to selectively target a specific protein responsible for bone dissolution, thereby reducing bone loss and improving bone density.
Overall, the successful completion of this Phase 1 study is an important step forward in the development of this innovative treatment for bone disorders. CuraTeQ Biologics’ work has the potential to bring a new and effective therapy to patients with osteoporosis and related conditions, and the company is committed to advancing this research through further clinical trials and regulatory submissions.
US Announces Plans to Impose Tariffs on Pharma Imports: Impact on India’s $8.7 Billion Market
The US government, under President Donald Trump, has announced plans to impose new tariffs on pharmaceutical imports, which could significantly impact India, the top supplier of generic drugs to the US. The move aims to push pharmaceutical manufacturing back to the US, but analysts warn that it could have far-reaching consequences for both countries. India’s pharmaceutical sector, which generates a significant portion of its revenue from the US market, could face major setbacks. Indian companies such as Dr Reddy’s, Aurobindo Pharma, Sun Pharma, Zydus Lifesciences, and Gland Pharma, which rely on the US market for a substantial part of their revenue, may be particularly affected.
The tariffs, expected to be “major,” could lead to increased costs for US consumers and insurers, and potentially cause inflation and drug shortages. The US heavily relies on low-cost Indian generics to maintain affordability in healthcare, and a tariff regime could disrupt this arrangement. Indian drugmakers already operate on tight margins, and tariffs would force them to raise prices, making their products less competitive in the US market.
As the US government continues to develop its trade policy, Indian pharma exports may face an uncertain future, further adding pressure to the industry grappling with FDA compliance challenges. The US-India trade relationship is already under strain, and the tariff move could exacerbate tensions between the two nations. Analysts warn that both countries will bear the brunt of this move, which could set back India’s competitiveness in the global pharmaceutical market.
Citi cites low risk of US tariffs on Indian pharma, favoring Torrent Pharma and Divi’s.
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as Zydus, Dr. Reddy’s Laboratories, and Aurobindo Pharma, could face a 9-12% reduction in earnings before interest, taxes, depreciation, and amortization (EBITDA). However, if part of the tariffs is passed on to buyers, the impact could be reduced to 5-6%.
On the other hand, companies with lower exposure to US generics, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories, would be less affected, with an estimated 1-3% hit to EBITDA. Citi’s preferred picks in the Indian pharmaceutical sector, these companies have diversified portfolios and are less reliant on the US generics market.
The report also notes that if tariffs are imposed, they may not be fully passed on to US buyers due to various factors, including competition, industry fragmentation, and the influence of buying consortiums focused on lowering prices. Citi believes that the probability of tariffs on Indian generics is low, citing the limited manufacturing of generics in the US, the high dependence on Indian generics, and the risk of drug shortages if Indian suppliers exit the market.
The brokerage firm concludes that while the imposition of tariffs is a low-probability event, the potential impact on Indian pharmaceutical companies varies significantly based on their exposure to the US generics market. Overall, the report suggests that investors should focus on companies with diversified portfolios and lower reliance on the US generics market, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories.
Aurobindo Pharma Terminates Vaccine License Agreement with Hilleman Labs
Aurobindo Pharma, a pharmaceutical company, has terminated its licensing agreement with Hilleman Laboratories Singapore Pte Ltd for the development, manufacturing, and commercialization of a pediatric pentavalent vaccine candidate. The agreement was signed in September 2023 and was set to expire in 2025. As Auro Vaccines, the subsidiary responsible for the vaccine development, is not a material part of the company, Aurobindo Pharma expects the termination to have no significant impact on its financials or subsidiaries.
The agreement required Auro Vaccines to make milestone payments to Hilleman Laboratories upon achieving specific development and clinical study outcomes, as well as pay royalties to the Singapore-based company once the vaccine candidate was commercialized. Despite the termination, Aurobindo Pharma is not expected to experience any significant impact, and the company will make any necessary disclosures if the situation changes in the future.
The termination is viewed as a “non-material event” by Aurobindo Pharma, which suggests that the company does not expect to incur any substantial financial losses or liabilities as a result. This decision may indicate that the company is re-evaluating its priorities and focusing on more promising opportunities. As the deal was still in its early stages, the termination may not have significant implications for the pharmaceutical industry or the development of pediatric vaccines.
Unleashing New Frontiers: Aurobindo Pharma’s Diversification Drive Paves the Way for Future Growth
Aurobindo Pharma, a leading drugmaker, is focusing on sustaining profitability and turnover in the face of rising global uncertainties. According to Chief Financial Officer Santhanam Subramanian, the company’s strategy is centered on scale and diversity, with a goal of expanding into new verticals such as injectables, peptides, and biosimilars. This diversification will help minimize the impact of a potential tariff hike in the US and maintain margins.
Aurobindo has been steadily expanding its presence in the market, starting with a small API business in India, followed by the US, Europe, and other parts of the world. The company is also entering the Chinese market, which is expected to contribute to its growth in 2-3 years.
The company’s diversified portfolio allows it to overcome the risks associated with price erosion, as 10% of its top products account for 20% of its US turnover. Aurobindo does not differentiate between “bread and butter” and high-growth segments, nurturing all verticals independently to ensure consistent contribution to overall growth.
In terms of cash flow generation, Aurobindo is planning to expand its existing projects and open new plants, including a US-based plant and a biosimilar facility. The company’s strong cash flow generation allows it to strategically allocate capital towards new verticals and expansion projects.
Aurobindo’s net debt stands at $84 million, with projections to generate $200-300 million annually. The company has a robust product pipeline, with over 850 ANDAs filed and 150-200 awaiting approval. The new verticals of biosimilars, Eutect, Terany, and Biologics are expected to drive growth in the coming years.
Overall, Aurobindo Pharma is confident in its ability to sustain healthy margins and drive growth through its focus on scale and diversity, robust cash flow generation, and strong product pipeline.